Title 41, Public Health

(1) A manufacturer or distributor shall not deny, restrict, prohibit, or otherwise interfere with, either directly or indirectly, the acquisition of a 340B drug by, or delivery of a 340B drug to, a pharmacy that is under contract with a 340B entity and is authorized under such co…

This chapter may be known and shall be cited as the “Protecting Patient Access to Physician-Administered Drugs Act”.

The purpose and intent of the Protecting Patient Access to Physician-Administered Drugs Act is to ensure patient access to physician-administered drugs and related services furnished to persons covered under a health insurance contract. This chapter shall ensure that health insur…

(1) As used in this chapter, the following words have the meanings as defined in this section unless the context clearly indicates otherwise:(a) “Covered person” means a policyholder, subscriber, enrollee, member, or individual covered by a health insurance plan.(b) “Health insur…

(1) A health insurance issuer, pharmacy benefit manager, or the agent of either shall not:(a) Refuse to authorize, approve, or pay a participating provider for providing covered physician-administered drugs and related covered services to covered persons; or(b) Require a covered …

The commission of any act prohibited by this chapter is considered a violation of the Consumer Protection Act, Sections 75-24-1 through 75-24-29, and subjects the violator to any and all actions, including investigative demands, private actions, remedies, and penalties, provided …

(1) As used in this section, Section 27-103-305 and Section 27-103-305.1, the following terms shall have the meanings as defined in this subsection unless the context clearly requires otherwise:(a) “Council” means the Mississippi Opioid Settlement Fund Advisory Council created in…

This chapter shall be known as the Ibogaine Drug Development Clinical Trial Act.

The department, in its sole discretion, shall select a consortium established in accordance with Section 41-155-5 for the purpose of conducting an ibogaine drug development clinical trial under this chapter.

(1) As soon as practicable after selecting a consortium to conduct an ibogaine drug development clinical trial under Section 41-155-11, the department shall enter into an interagency contract with the lead institution of higher learning of the selected consortium to provide fundi…

(1) As soon as practicable after the department’s notification that a consortium is selected to conduct an ibogaine drug development clinical trial under this chapter, the consortium must enter into an agreement with the lead consortium after the lead consortium, whether acting t…

For purposes of conducting an ibogaine drug development clinical trial under this chapter, only an institution of higher learning or a hospital may serve as a trial site.

(1) The department and consortium members may solicit and accept gifts, grants, and donations of any kind received from sources other than the state for purposes of funding the drug development clinical trial under this chapter. (2) Disbursements of funds by the department may be…

(1) A consortium selected to conduct the ibogaine drug development clinical trial shall quarterly prepare and submit to the department:(a) A report on the progress of the drug development clinical trial conducted under this chapter; and(b) A financial status report, including inf…

(1) The revenue attributable to all intellectual property rights and other commercial rights arising from the drug development clinical trial conducted by a consortium under this act during the period for which the trial is funded and any following period of commercialization sha…

(1) This section applies only if ibogaine is approved by the FDA to treat a medical condition. (2) A physician licensed in this state who has prescribed ibogaine for a patient shall supervise the administration of ibogaine at a hospital or other licensed health care facility to e…

If before implementing any provision of this chapter, the department or another state agency determines that a waiver or authorization from a federal agency is necessary for implementation of that provision, the agency affected by the provision shall request the waiver or authori…

(a) As used in this chapter, the following terms shall be defined as provided in this section:(a) “Department” means the State Department of Health.(b) “Drug developer” means a pharmaceutical company, biotechnology company, or contract development and manufacturing organization e…

(1) A consortium may be established under this section and apply for selection by the department under this chapter to conduct a drug development clinical trial with ibogaine and secure the FDA’s approval of ibogaine as a medication for the treatment of:(a) Opioid use disorder;(b…

(1) A consortium established under this chapter shall select a lead institution of higher learning from among the consortium’s members to represent the consortium and perform administrative functions under this act, including contracting with and reporting to the department as re…

(1) The lead institution of higher learning of a consortium shall submit to the department a proposal for purposes of conducting an ibogaine drug development clinical trial in accordance with this chapter. (2) A proposal submitted under subsection (1) of this section must provide…